Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193833 | 0.88 | ADORA1 (0.52) | ADORA1MAPK1IGF1RMAPK14AKT1 | |
| SCHEMBL7373031 | 0.85 | ADORA1 (0.48) | ADORA1MAPK1IGF1RMAPK14EGFR | |
| SCHEMBL7654930 | 0.84 | ADORA1 (0.60) | ADORA1MAPK1IGF1RMAPK14MAPK3 | |
| SCHEMBL8810012 | 0.84 | ADORA1 (0.73) | ADORA1MAPK1IGF1RMAPK14MAPK3 | |
| SCHEMBL7039587 | 0.84 | ADORA1 (0.57) | ADORA1MAPK1IGF1RMAPK14MAPK3 | |
| SCHEMBL8197666 | 0.83 | ADORA1 (0.48) | ADORA1MAPK1IGF1RBRD4PDE5A | |
| SCHEMBL6822006 | 0.82 | ADORA1 (0.46) | ADORA1MAPK1IGF1REGFRBRD4 | |
| SCHEMBL7299166 | 0.82 | ADORA1 (0.77) | ADORA1MAPK1IGF1RMAPK14MAPK3 | |
| SCHEMBL7295203 | 0.82 | ADORA1 (0.73) | ADORA1MAPK1IGF1RMAPK14MAPK3 | |
| SCHEMBL5795745 | 0.82 | ADORA1 (0.55) | ADORA1MAPK1IGF1RMAPK14MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846951-B2 | Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090018140-A1 | THIAZOLES AND OXAZOLES USEFUL AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-15 | — | — | US | disclosed |
| EP-0379979-B1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-19 | — | — | EP | disclosed |
| US-5155114-A | Treating or preventing renal toxicity, nephrosis, nephritis | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-4985444-A | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0379979-A1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018140-A1 | THIAZOLES AND OXAZOLES USEFUL AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ADORA1 472/4885MAPK1 4297/4885IGF1R 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.